Insider buying
2 insiders2 directors
Open-market purchases, traded Nov 9 – Nov 10, 2026. Each amount is that person's own.
Ask OQRO reads the filings behind this page and answers in plain words, with a link to each source.
Ask OQRO is part of OQRO Pro. Everything else on OQRO is free.
Only to see which pages are hard to use, so we can fix them. Nothing is used for ads, and what you type stays hidden (Microsoft Clarity, PostHog). Privacy Policy
Checked for new insider filings 3 h ago
Guides: What is an SEC Form 4 · the transaction codes · who has to file · 10b5-1 plans
Worth a look: purchases of $10K+ and sales of $250K+ not reported under a pre-arranged trading plan.
Insider buying
Open-market purchases, traded Nov 9 – Nov 10, 2026. Each amount is that person's own.
Lately at Amdocs: the stock fell 30% in one session on Nov 4 with press coverage; the stock is down 33% in 30 days; insiders made 7 purchases ($10K+) and 2 large sales ($250K+, not pre-arranged) in 90 days.
Insider buying
First insider buy since Jun 2025Traded Nov 11 · filed 1 day later
Since the trade −7.5% · S&P 500 −9.2% · to Nov 20
Bought 19% below the 52-week high, RSI 51, 11 points ahead of the S&P 500 over 3 months
A Regional Management director paid $230K out of pocket for Regional Management shares. It was the first purchase in 21 months.
Lately at Regional Management: it changed a top executive or board member on Oct 28; insiders made 3 purchases ($10K+) and 2 large sales ($250K+, not pre-arranged) in 90 days.
Insider buying
First insider buy since Jun 2022Traded Nov 10 · filed 2 days later
Since the trade −1.7% · S&P 500 −8.0% · to Nov 20
Bought 47% below the 52-week high, RSI 31, 16% under its 200-day average, 18 points behind the S&P 500 over 3 months
An Aquestive Therapeutics director paid $95K out of pocket for Aquestive Therapeutics shares. Shares held went up 2235% with this purchase.
Lately at Aquestive Therapeutics: it reported its results on Nov 3; the stock is down 15% in 30 days.
Insider buying
Traded Nov 11 · filed 1 day later
Since the trade −7.3% · S&P 500 −9.2% · to Nov 20
Bought within 4% of the 52-week low, RSI 45, 15% under its 200-day average, 12 points behind the S&P 500 over 3 months
The CEO of Frp paid $78K out of pocket for Frp shares. 1 other person at Frp bought some too, in the same month.
Lately at Frp Holdings: it reported its results on Nov 4; the stock is down 7% in 30 days; insiders made 5 purchases ($10K+) and no large sale ($250K+, not pre-arranged) in 90 days.
Insider buying
6 insiders in a week, a first since 2014Traded Nov 11 · filed 1 day later
Since the trade +15.0% · S&P 500 −9.2% · to Nov 20
Bought 54% below the 52-week high, RSI 53, 28% under its 200-day average, 34 points behind the S&P 500 over 3 months
Larimar Therapeutics's Chief Development Officer paid $14K out of pocket for Larimar Therapeutics shares. 8 other people at Larimar Therapeutics bought some too, in the same month. It was the first purchase in over a year.
Lately at Larimar Therapeutics: the stock fell 16% in one session on Nov 5 with press coverage; it reported its results on Nov 16; the stock is up 30% in 30 days.
Insider buying
First insider buy since Aug 2025Traded Nov 11 · filed 1 day later
Since the trade −11.7% · S&P 500 −9.2% · to Nov 20
Bought 33% below the 52-week high, RSI 29, 28% above its 200-day average
The CEO of Atlassian paid $109K out of pocket for Atlassian shares. It was the first purchase in over a year.
Lately at Atlassian: the stock fell 16% in one session on Nov 6 around a company release; it changed a top executive or board member on Nov 5; the stock is down 40% in 30 days.
Insider buying
Traded Nov 11 · filed 1 day later
Since the trade −10.6% · S&P 500 −9.2% · to Nov 20
Bought 26% below the 52-week high, RSI 45, 10% under its 200-day average, 18 points behind the S&P 500 over 3 months
A Hexcel director paid $81K out of pocket for Hexcel shares. Shares held went up 31% with this purchase.
Lately at Hexcel: it reported its results on Oct 21; the stock is down 19% in 30 days; insiders made 2 purchases ($10K+) and 2 large sales ($250K+, not pre-arranged) in 90 days.
Insider buying
3 insiders in a week, 6th time since 2021Traded Nov 10 · filed 2 days later
Since the trade −6.6% · S&P 500 −8.0% · to Nov 20
Bought 7% below the 52-week high, RSI 65, 17% above its 200-day average, 27 points ahead of the S&P 500 over 3 months
An Advanced Flower Capital director paid $69K out of pocket for Advanced Flower Capital shares. 2 other people at Advanced Flower Capital bought some too, in the same month.
Lately at Advanced Flower Capital: the stock rose 14% in one session on Nov 17 with press coverage; it reported its results on Nov 5; the stock is up 9% in 30 days.
Insider buying
Traded Nov 11 · filed 1 day later
Since the trade −28.3% · S&P 500 −9.2% · to Nov 20
Bought 48% below the 52-week high, RSI 33, 2% under its 200-day average, 21 points behind the S&P 500 over 3 months
A major shareholder of Exagen paid $373K out of pocket for Exagen shares.
Lately at Exagen: the stock fell 26% in one session on Nov 10 around a company release; it reported its results on Nov 10; the stock is down 54% in 30 days.
Insider buying
Largest insider buy since 2006Traded Nov 11 · filed 1 day later
Since the trade −4.6% · S&P 500 −9.2% · to Nov 20
Bought 14% below the 52-week high, RSI 40
An Investors Title director paid $133K out of pocket for Investors Title shares. Shares held went up 13% with this purchase.
Lately at Investors Title: it reported its results on Nov 5; the stock is down 13% in 30 days.
Insider buying
Named in an 8-K 14 days earlierTraded Nov 11 · filed 1 day later
Since the trade −30.1% · S&P 500 −9.2% · to Nov 20
Bought at the 52-week low, RSI 33, 54% under its 200-day average, 49 points behind the S&P 500 over 3 months
The CFO of Ur-Energy paid $20K out of pocket for Ur-Energy shares. 1 other person at Ur-Energy bought some too, in the same month. It was the first purchase in over a year.
Lately at Ur-Energy: it reported its results on Nov 9; the stock is down 48% in 30 days; insiders made 5 purchases ($10K+) and no large sale ($250K+, not pre-arranged) in 90 days.
Insider buying
10 days before resultsTraded Nov 9 · filed 3 days later
Since the trade +21.1% · S&P 500 −8.3% · to Nov 20
Bought 44% below the 52-week high, RSI 55, 8% under its 200-day average, 36 points ahead of the S&P 500 over 3 months
A major shareholder of San Juan Basin Royalty Trust paid $330K out of pocket for San Juan Basin Royalty Trust shares.
Lately at San Juan Basin Royalty Trust: the stock rose 17% in one session on Nov 10; it reported its results on Nov 19; the stock is up 29% in 30 days.
Traded Nov 12, 2026 · largest single transaction ~$66.6MNot reported under a pre-arranged trading plan
Lately at Alphabet: the stock fell 13% in one session on Oct 29 around a company release; it reported its results on Oct 28; the stock is down 21% in 30 days.
Nov 12, 2026~$66.6M · 227K shares, around Nov 12, 2026
DetailsOfficial recordNov 12, 2026~$66M · 227K shares, around Nov 12, 2026
DetailsOfficial recordInsider buying
Traded Nov 10 · filed 2 days later
Since the trade −12.8% · S&P 500 −8.0% · to Nov 20
Bought within 2% of the 52-week low, RSI 23, 28% under its 200-day average, 28 points behind the S&P 500 over 3 months
A Mach Natural Resources director paid $502K out of pocket for Mach Natural Resources shares.
Lately at Mach Natural Resources LP: it signed an important agreement on Nov 19; the stock is down 25% in 30 days; insiders made 2 purchases ($10K+) and no large sale ($250K+, not pre-arranged) in 90 days.
Insider selling
Traded Nov 12 · filed the same day
A major shareholder of Fermi told the SEC about a plan to sell $20.6M of Fermi shares around Nov 12, 2026. The shares were not acquired as compensation. That is 1.6% of all Fermi shares.
Lately at Fermi: the stock rose 27% in one session on Nov 13 around a company release; it reported its results on Nov 12; the stock is down 32% in 30 days.
Insider buying
First insider buy since Jun 2025Traded Nov 11 · filed 1 day later
Since the trade −26.7% · S&P 500 −9.2% · to Nov 20
Bought 87% below the 52-week high, RSI 34, 74% under its 200-day average, 74 points behind the S&P 500 over 3 months
The CEO of Airsculpt Technologies paid $24K out of pocket for Airsculpt Technologies shares. It was the first purchase in 18 months.
Lately at Airsculpt Technologies: it signed an important agreement on Nov 6; the stock is down 54% in 30 days.
Insider buying
3 days before an 8-KTraded Nov 9 · filed 3 days later
Since the trade −35.5% · S&P 500 −8.3% · to Nov 20
A major shareholder of Big Digital Energy paid $37K out of pocket for Big Digital Energy shares. Shares held went up 39% with this purchase.
Lately at Big Digital Energy: the stock rose 20% in one session on Nov 6 around a company release; it changed a top executive or board member on Nov 18; the stock is down 53% in 30 days.
Insider buying
Traded Nov 11 · filed 1 day later
Since the trade −30.3% · S&P 500 −9.2% · to Nov 20
Bought 62% below the 52-week high, RSI 75, 14% under its 200-day average, 43 points ahead of the S&P 500 over 3 months
The CEO of Neonc Technologies paid $45K out of pocket for Neonc Technologies shares. 1 other person at Neonc Technologies bought some too, in the same month.
Lately at Neonc Technologies Holdings: it reported its results on Nov 5; the stock is up 9% in 30 days; insiders made 8 purchases ($10K+) and no large sale ($250K+, not pre-arranged) in 90 days.